BCV
ABCL icon

Banque Cantonale Vaudoise’s AbCellera Biologics ABCL Stock Holding History

Banque Cantonale Vaudoise’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-6,284
Closed -$47K – 1172
2023
Q1 		$47K Sell
6,284
-26,792
-81% -$243K ﹤0.01% 971
2022
Q4 		$335K Sell
33,076
-10,902
-25% -$126K 0.02% 561
2022
Q3 		$435K Buy
43,978
+37,694
+600% +$414K 0.02% 508
2022
Q2 		$67K Buy
+6,284
New +$53.2K ﹤0.01% 947

Other funds holding ABCL

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
FFVM
Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Banque Cantonale Vaudoise's ABCL Position: Q2 2023 in Review

Banque Cantonale Vaudoise sold out of AbCellera Biologics (ABCL) in Q2 2023, closing a stake of 6,284 shares — an estimated $47K sold.

Banque Cantonale Vaudoise first reported a position in ABCL in Q2 2022 and held it in 4 quarters. The position peaked at $435K in Q3 2022. 169 funds tracked by Wall St. Rank hold ABCL as of Q2 2023.

  • Banque Cantonale Vaudoise reported no remaining AbCellera Biologics position as of Q2 2023 after selling out during the quarter.
  • Banque Cantonale Vaudoise sold 6,284 AbCellera Biologics shares in Q2 2023, an estimated $47K.
  • Banque Cantonale Vaudoise first reported a position in AbCellera Biologics in Q2 2022 and held it in 4 quarters.
  • Banque Cantonale Vaudoise's AbCellera Biologics position peaked at $435K in Q3 2022.
  • 169 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2023.

Based on Banque Cantonale Vaudoise's 13F filing for Q2 2023, filed 9 Aug 2023.